Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor

We love to hear from our listeners. Send us a message. (buzzsprout.com/1011661/fan_mail/new)
On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing and delivery strategy, workforce constraints, and building a clinical strategy around receptor positivity across tumor types.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (lifescienceleader.com/solution/the-business-of…) tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter (www9.lifescienceleader.com/business-of-biotech…).

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: linkedin.com/in/bencomer